Transforming drug discovery
The School of Chemistry is leading a £3.4M programme that will facilitate the discovery of new drugs against protein-protein interactions.
Currently, only a handful of drugs in clinical use work by targeting protein-protein interactions.
There are thought to be as many as 600,000 protein-protein interactions that could be targets for new drugs but we don’t know which ones are most important, what is crucial for their interaction and how to target them.
This new project, which will launch on 1 February, 2016, will involve researchers from the University of Leeds, the University of Bristol and three drug discovery organisations: the Northern Institute for Cancer Research, Newcastle University; AstraZeneca; and Domainex.
The project is led by Professor Andy Wilson, and will also involve Professor Adam Nelson from the School of Chemistry.
